Australian employers in safety-critical industries can conduct random drug testing where a compliant policy authorises it and the testing follows AS 4308:2023 (urine) or AS 4760:2019 (oral fluid). The policy must be clearly communicated, applied consistently, and proportionate to the safety risks of the role. A positive test result alone does not mean impairment, and disciplinary outcomes must be managed in accordance with the Fair Work Act 2009 and any applicable enterprise agreement.
The legal basis for random testing in Australia
There is no single national statute that expressly authorises or prohibits workplace drug testing. The legal basis is assembled from several sources, and the gaps between them create real exposure for employers who assume they can test simply because they want to.
The primary legal foundation is the employment contract or enterprise agreement. Where a drug and alcohol policy is incorporated into the contract of employment — either directly or by reference — and that policy clearly authorises random testing, the employer can lawfully direct workers to submit to a test. The direction is a reasonable and lawful direction under the contract, not a separate consent event. Workers who refuse a lawful direction may face disciplinary action.
The Work Health and Safety Act 2011 (model WHS Act) creates the positive duty context: employers must eliminate or minimise reasonably foreseeable risks so far as is reasonably practicable. Where drug or alcohol impairment is a reasonably foreseeable cause of harm in a role — which it clearly is in mining, construction, transport, and manufacturing — a testing program is one mechanism for discharging that duty. This is the justification argument for why the policy is reasonable, not itself a stand-alone testing authority.
Enterprise agreements in safety-critical industries often specify the testing mechanism, selection method, consequence framework, and appeal rights in detail. Where an enterprise agreement exists, it overrides a unilateral employer policy on those matters. Always check the enterprise agreement before implementing or modifying a random testing program.
AS 4308:2023 and AS 4760:2019 — which standard applies and why it matters
Choosing the wrong testing matrix is one of the most common and consequential errors in Australian workplace drug programs. The two standards have fundamentally different detection windows and different relationships to impairment — and they are not interchangeable.
| Feature | AS 4308:2023 — Urine | AS 4760:2019 — Oral Fluid |
|---|---|---|
| Detection window (cannabis) | 3–30 days (metabolites) | 4–24 hours (parent drug) |
| Relationship to impairment | Indicates recent to historical use | More closely aligned with recent use |
| Specimen collection | Observed or unobserved void | Swab — less privacy-intrusive |
| Primary industry use | Pre-employment, post-incident | Random, for-cause, post-incident |
| Confirmatory method | GC-MS or LC-MS/MS | LC-MS/MS |
| Point-of-care devices | Common, well-validated | Available, fewer validated devices |
For random testing programs in safety-critical industries, oral fluid (AS 4760:2019) has become the preferred matrix because the detection window better reflects recent use. A miner who smoked cannabis three weeks ago and is demonstrably not impaired today generates a positive urine result — a result that is difficult to act on proportionately and that can generate unfair dismissal risk. Oral fluid narrows that gap considerably, though it does not eliminate it.
Chain of custody: the procedural failure that invalidates results
Every positive result that proceeds to disciplinary action will be scrutinised. The chain of custody documentation is the evidentiary backbone of the entire process — and it is the first thing a worker’s legal representative will challenge.
A complete and defensible chain of custody requires each of the following steps to be documented with the collector’s signature, the worker’s signature, and timestamps:
Identity verification
Worker’s identity confirmed by photo ID before collection. Name and employee number recorded on the chain of custody form.
Collection procedure
Conducted strictly in accordance with AS 4308:2023 or AS 4760:2019 as applicable. Temperature strips completed for urine; device instructions followed for oral fluid. Collector must be trained and, for urine, certified under applicable standard.
Specimen sealing and labelling
Specimen sealed in the worker’s presence. Tamper-evident seal applied. Worker signs across the seal. Every element of the label — name, date, time, donor signature — completed before the specimen leaves the worker’s direct line of sight.
Custody transfer
Each transfer of the specimen — collector to courier, courier to laboratory — documented on the chain of custody form with signatures and timestamps. Any gap in documentation is a chain of custody break.
Laboratory accreditation
Confirmatory testing must be performed by an NATA-accredited laboratory. The laboratory report must specify the confirmatory method (GC-MS or LC-MS/MS), the quantitated result, and the cutoff applied.
Managing a positive result — the process that matters more than the policy
A confirmed positive result from an NATA-accredited laboratory is the starting point, not the ending point. The employer’s response determines whether the program achieves its safety objective and whether any disciplinary outcome is defensible.
The first step after receiving a confirmed positive is a medical review. A medical review officer (MRO) — an occupational physician trained in drug testing interpretation — reviews the laboratory result, contacts the worker to discuss any legitimate medical explanation (prescription medication, medical treatment), and provides the employer with a verified medical opinion on the result. This step is legally protective: it is where the Disability Discrimination Act 1992 obligations are met for workers with legitimate prescription drug use.
After the MRO review, the employer follows the consequence framework in the policy or enterprise agreement. In most safety-critical industry programs, this involves: immediate removal from safety-critical duties on a confirmed positive; a formal show-cause process; a defined pathway of assessment, treatment, and monitored return; and consequences for a second positive or refusal to participate in the return-to-work pathway.
Under the Fair Work Act 2009, any dismissal for drug or alcohol policy breach must satisfy the “valid reason” and “procedural fairness” tests. Valid reason requires the dismissal to be connected to the worker’s capacity or conduct. Procedural fairness requires the worker to have been notified of the allegation, given an opportunity to respond, and informed of the potential consequences. Even in safety-critical industries with strong enterprise agreement consequence frameworks, process matters. Document every step.
The legislative framework that governs every decision
No single Act governs workplace drug testing. Any employer implementing or managing a program needs working knowledge of at least four instruments.
Work Health and Safety Act 2011 (model WHS Act)
Creates the positive duty to manage foreseeable risks, including impairment. The justification for why a drug and alcohol testing program is a reasonable measure. Also imposes obligations on workers to not attend work impaired — section 28.
Fair Work Act 2009
Governs the procedural requirements for any disciplinary outcome, including dismissal. Sections 385–387 set out the criteria for unfair dismissal — valid reason, notification, opportunity to respond, support person rights, and consistency of treatment.
Disability Discrimination Act 1992 (Cth)
Prohibits discrimination on the basis of a disability, including substance use disorders that qualify as a disability. Employers must consider whether a worker with a substance use disorder can meet the inherent requirements of their role with reasonable adjustment before taking adverse action.
Privacy Act 1988 (Cth) — Australian Privacy Principles
Drug test results are sensitive health information under APP 3. Collection requires informed consent (through the policy, at commencement) or direct necessity for the employer function. Results must be stored securely and not used for purposes beyond what was disclosed.
State WHS regulations and mining/transport legislation
Queensland, Western Australia, and Northern Territory have specific provisions for drug and alcohol testing in the resources sector. Transport regulation under the Heavy Vehicle National Law imposes additional obligations on operators of regulated heavy vehicles. State-specific requirements may impose testing obligations beyond the employer's own policy.
Frequently asked questions
Can an Australian employer conduct random drug testing without consent?
Yes — where a workplace drug and alcohol policy forms part of the employment contract or enterprise agreement, and the policy clearly authorises random testing, an employer can lawfully direct workers to submit to random drug testing without individual consent at the point of testing. The legal basis is the employment contract or enterprise agreement, not consent at the time of selection. For this to be defensible, the policy must have been clearly communicated to workers before commencement, applied consistently, and be proportionate to the safety risks of the role.
Which Australian standard applies to urine drug testing?
AS 4308:2023 (Procedures for the collection, detection and quantitation of drugs of abuse in urine) is the applicable Australian Standard for urine-based workplace drug testing. It specifies collection procedures, initial screening cutoffs, confirmatory testing requirements by GC-MS or LC-MS/MS, chain of custody requirements, and laboratory accreditation. Compliance with AS 4308:2023 is the benchmark for defensible positive test management. For oral fluid testing, AS 4760:2019 applies.
What drugs are detected in a standard AS 4308 urine screen?
A standard AS 4308:2023 urine screen typically covers: cannabis (THC-COOH), amphetamines and methylamphetamine, cocaine metabolites (benzoylecgonine), opioids (morphine and codeine at 300 µg/L cutoff), and benzodiazepines. Many safety-critical industry programs extend the panel to include MDMA, buprenorphine, oxycodone, and fentanyl. The initial screen uses immunoassay; any non-negative result must be confirmed by GC-MS or LC-MS/MS before a positive is reported to the employer.
Does a positive drug test always mean the worker was impaired?
No. A positive urine drug test indicates that a metabolite of the drug was present in urine above the AS 4308:2023 cutoff at the time of collection. It does not establish impairment at that moment, nor does it establish when the drug was consumed. Cannabis metabolites, for example, can be detectable in urine for 3–30 days after use depending on frequency of use and metabolism. This is why many safety-critical industries have moved to AS 4760:2019 oral fluid testing, which has a shorter detection window more closely aligned with recent use and likely impairment. Employers should not conflate a positive urine test with present impairment in their disciplinary process.
Can an employer dismiss a worker for a first positive drug test?
This depends on the role, the enterprise agreement or employment contract, the employer's policy, and the surrounding circumstances. In safety-critical roles (mine site operators, heavy vehicle drivers, crane operators), some enterprise agreements provide for immediate suspension and a structured management pathway on a first positive, with termination for a second positive or refusal to participate. In non-safety-critical roles, dismissal for a first positive without a documented escalation pathway is more likely to face unfair dismissal challenge under the Fair Work Act 2009. The employer's policy must be clear, proportionate, and consistently applied. Legal advice should be obtained before terminating on a first positive in any context.
What obligations does an employer have if a worker discloses a prescription for a prescribed drug?
Where a worker discloses a prescription for a drug that would generate a positive result (opioids, benzodiazepines, some stimulants), the employer has obligations under the Disability Discrimination Act 1992 to consider whether the worker can meet the inherent requirements of their role with reasonable adjustment. The medical review officer (MRO) or occupational physician should assess whether the prescribed medication, at the stated dose, is likely to impair the worker's capacity to safely perform their role's safety-critical functions. If it does not impair capacity, the test result should be managed as a medical information matter rather than a disciplinary one. Workers should always notify their employer before testing if they are taking prescribed medications that may affect the result.
Drug & Alcohol Testing — Service Overview
OccuSpan's end-to-end drug and alcohol testing management platform.
Fitness for Work Assessment
When a fitness for work assessment is required and what it measures.
Pre-Employment Screening Guide
IROJ-calibrated pre-employment screening framework for Australian employers.
Psychosocial Risk Management
Managing psychosocial hazards under ISO 45003:2021 and the model WHS Act.
OccuSpan
Drug and alcohol testing — managed from policy to outcome in one platform
OccuSpan manages the full drug and alcohol testing lifecycle: compliant collection scheduling, chain of custody documentation, MRO review workflow, and disciplinary outcome tracking — all linked to the worker record and audit trail.
See the D&A testing module